Introduction {#S1}
============

Dopamine (DA) signaling underlies many neural functions. Dopaminergic afferents from the midbrain DA nuclei innervate the striatum, amygdala, hippocampus, and prefrontal cortex (PFC), where D~1~- and D~2~-like receptors differentially regulate neuronal function. D~1~ receptors are exclusively post-synaptically expressed, and D~1~ binding activates intracellular signaling cascades that tend to increase the likelihood of neuronal firing ([@R1]). In contrast, D~2~ receptors are expressed both pre-synaptically, where they act as autoreceptors that regulate DA release, and post-synaptically, where their binding inhibits the same intracellular cascades enhanced by D~1~ binding ([@R2], [@R3]). In the PFC, where D~1~ expression predominates ([@R4]), the "dual state" theory holds that D~1~ and D~2~ receptors oppose each other in their effects on cognitive function: when PFC signaling is dominated by D~2~ binding, cortical networks favor flexible processing, whereas when signaling is D~1~-dominated, networks favor stabilizing information and protecting it from interference ([@R5]). Striatal DA signaling, which is more D~2~-dependent, has greater effects on the former kind of cognition ([@R6]), although corticostriatal connections allow interactions between striatal and cortical DA neurons ([@R7]). In contrast, phasic DA release in the PFC, which increases D~1~ and reduces D~2~ activation ([@R8]), modulates cognitive functions that depend upon the PFC, including working memory, selective attention, and executive function ([@R9]). Many theories posit that the relationship between cortical DA and PFC-dependent cognitive function is inverted-U-shaped, with both high and low cortical DA tone associated with impaired function ([@R9]--[@R12]).

In most brain areas, including the striatum, synaptic DA is rapidly inactivated primarily through active reuptake at the presynaptic dopamine transporter (DAT). In the PFC, however, the DAT is not highly expressed ([@R13]), and the principal method of DA inactivation is enzymatic degradation by catechol-*O*-methyltransferase (COMT) ([@R14]). COMT inactivates DA more slowly than the DAT, causing DA effects to persist much longer in the PFC and allowing the DA signal to stabilize and protect information. A common single nucleotide polymorphism (SNP) at codon 158 in *COMT*, the gene that encodes this enzyme, has been associated with differential COMT function, and, accordingly, differential cortical synaptic DA accumulation. Specifically, the met (A) allele of the val158met SNP (rs4680), which causes a valine to methionine amino acid substitution, is associated with a three- to four-fold reduction in COMT efficacy, and thus greater cortical DA tone, relative to the val (G) allele ([@R15], [@R16]). The higher DA met allele may also be associated with a more optimal D~1~/D~2~ balance, while the lower DA val allele may be associated with a low D~1~/high D~2~ state ([@R5], [@R17]) (see [Figure 1](#F1){ref-type="fig"}).

The val158met SNP is among the most thoroughly studied genetic variants in psychiatry ([@R18], [@R19]). Disruption of corticostriatal DA signaling is a core feature of neuropsychiatric disorders characterized by cognitive symptoms, including attention-deficit/hyperactivity disorder (ADHD) and schizophrenia ([@R20], [@R21]), and early studies tested the association between val158met variation and these disorders. However, meta-analyses ultimately revealed no associations with these diagnoses ([@R22], [@R23]). Attention then turned to associations between val158met and cognitive function, an intermediate phenotype theoretically more proximal to the neuronal level than diagnostic phenotypes. Although initial studies suggested an association between val158met variation and cognition in both clinical samples and healthy controls ([@R24]--[@R26]), subsequent meta-analyses also found no effect on this phenotype ([@R27]). Thus, despite the SNP's clear proximal effects on enzymatic function, its distal effects on behavior have remained ambiguous ([@R28]).

One factor that may account for these mixed findings is that *COMT* val158met variation is only one of many influences on cognitive function, which, although "intermediate" between neuronal signaling and disease outcomes, is a highly complex phenotype ([@R29]). In contrast, drug response phenotypes, while themselves complex, are, relative to diagnostic phenotypes, potentially more strongly affected by variation in genes that directly control the neurobiological systems the drugs entrain ([@R30]). Broadly speaking, D~1~ agonists enhance PFC-dependent cognitive functions ([@R31]--[@R33]), while D~1~ antagonists impair them ([@R34]). D~2~ antagonist effects are more mixed ([@R35], [@R36]), perhaps due to these drugs' dose-dependent effects on pre- vs. post-synaptic D~2~ receptors ([@R37]). Recent reviews have summarized the interaction between val158met genotype and the effects of tolcapone ([@R38]) and risperidone ([@R39]), but neither addressed drug effects on cognitive function specifically, and the most recent systematic review of val158met effects on all dopaminergic drugs was published a decade ago ([@R40]). Thus, this manuscript critically reviews studies that have tested the pharmacogenetic interaction between *COMT* val158met genotype and the effects of dopaminergic drugs on PFC-dependent cognitive functions.

Method {#S2}
======

Study identification and selection {#S3}
----------------------------------

Studies were identified via PubMed searches conducted in April 2016 that included pairwise combinations of the terms "COMT", "catechol-*O*-methyltransferase", "val158met", or "rs4680", and "dopamine", "medication", "drug", "stimulant", or "antipsychotic". Studies that tested an interaction between val158met genotype and therapeutic drug effects on PFC-dependent cognitive functions (working memory, selective attention, and/or executive function) were included, whether these functions were evaluated in isolation or as part of larger cognitive batteries or symptom measures (e.g., a broader IQ assessment that included a working memory subtest or an ADHD symptom measure that assessed inattention). Studies of non-cognitive therapeutic effects (e.g., mood symptoms, COMT blood levels) were not included, nor were those of adverse effects, such as antipsychotic-induced tardive dyskinesia. This process ultimately identified 25 studies, which were grouped according to whether the effects of the drugs used were more D~1~- (e.g., stimulants, COMT inhibitors) or D~2~-dependent (e.g., antipsychotics).

Study designs {#S4}
-------------

Identified studies employed both double-blind, placebo-controlled designs and quasi-experimental designs, which used no placebo and compared cognitive function either between genotype groups or as a function of genotype and time. Most of the placebo-controlled studies also used within-subjects crossover designs. Nearly all studies employed longitudinal designs, but treatment length and number of assessment points varied widely. Several studies used prospective genotyping to employ an "extreme groups" design in which only individuals with homozygous genotypes (e.g., val/val or met/met) were included, but most genotyping was conducted *post hoc*, suggesting that experimenters were blind to genotype during outcome measure assessment. However, the use of genotype blinding was inconsistently reported across studies, precluding identification of those that used a double blind approach.

Outcome measures {#S5}
----------------

Symptom measures rated by clinicians, parents, and/or teachers were common for studies of individuals with ADHD, and were analyzed both continuously and categorically, with a range of categorical cut-points used to define symptom reduction for the latter approach. Neuropsychological tests were frequently used in studies of healthy controls and individuals with schizophrenia spectrum disorders, including both full neuropsychological batteries, such as the Wechsler Adult Intelligence Scale (WAIS), and subtests intended to measure specific PFC-dependent cognitive functions. Several studies used neuroimaging methods, including functional magnetic resonance imaging (fMRI) and electroencephalography (EEG), to measure brain response during cognitive task performance.

Results {#S6}
=======

Stimulants and COMT inhibitors {#S7}
------------------------------

Two classes of drugs acutely increase DA concentrations, leading to increased cortical D~1~ binding: stimulants (e.g., amphetamine, methylphenidate), which increase DA directly in the striatum through competitive reuptake at the DAT and indirectly in the PFC through downstream D~1~ effects ([@R41], [@R42]); and COMT inhibitors, which, in the treatment of Parkinson's disease, are commonly co-administered with L-DOPA to prevent its peripheral metabolism, but which also increase brain DA (primarily in the PFC) if they cross the blood-brain barrier ([@R43]). [Table 1](#T1){ref-type="table"} lists studies that have tested moderation of the cognitive effects of these drugs by *COMT* val158met variation.

Several large, placebo-controlled studies of amphetamine among healthy controls suggest weak evidence for pharmacogenetic moderation of stimulant effects. Although one small early study of amphetamine demonstrated greater improvement in executive function and working memory, relative to placebo, among val/val subjects administered amphetamine ([@R44]), subsequent larger studies have mostly failed to find this interaction. Notably, although one larger study reported greater amphetamine-induced improvements in selective attention among val-allele carriers ([@R45]), an attempted replication of this finding by the same group was negative ([@R46], [@R47]). The authors attributed this discrepancy to a failure to fully correct for multiple testing and to their own bias for publishing a positive pharmacogenetic effect but not negative ones; these issues represent challenges for many pharmacogenetic studies.

Evidence for pharmacogenetic moderation of stimulant effects is somewhat stronger among psychiatric populations. Most studies have focused on methylphenidate effects on ADHD symptoms among children with this disorder. Of seven such studies, four found greater reduction in ADHD symptoms among val/val subjects administered methylphenidate ([@R48]--[@R51]). All four studies used ADHD symptom rating scales, which combine inattentive and hyperactive symptoms, as endpoints; two ([@R49], [@R51]) analyzed these symptom clusters separately, and identified pharmacogenetic effects specifically for hyperactive symptoms, while the other two analyzed only total scale scores. Park et al. ([@R51]) also reported greater methylphenidate effects on a measure of inattention (response time variability on a continuous performance task) among val/val children. Of the remaining three studies of children with ADHD, two reported no pharmacogenetic interaction for combined symptoms ([@R52], [@R53]), and one found greater reduction in oppositional symptoms among male children with the val/met and met/met genotypes administered methylphenidate, although this effect did not persist beyond one month of treatment ([@R54]). A large study of adults with ADHD reported no pharmacogenetic effect on combined symptoms ([@R55]), but a smaller study of methylphenidate effects on hyperactivity among children with autism spectrum disorders found greater drug effects among val/val subjects ([@R56]). Study size and outcome measures did not predict whether studies reported a pharmacogenetic effect, but study design and population did. Only two of the four studies that used a stronger placebo-controlled crossover design reported a pharmacogenetic effect. Further, although the two studies that included only Korean subjects both reported pharmacogenetic effects ([@R48], [@R51]), the significantly lower frequency of the val158met met allele among individuals of East Asian descent raises the possibility that the small number of met-allele homozygotes in these studies may have driven these effects.

In contrast to the findings for stimulants, there is stronger evidence of pharmacogenetic moderation of COMT inhibitors, although studies have been limited by small samples, and have included mostly healthy controls. Three placebo-controlled studies of tolcapone among healthy controls found better performance on executive function, working memory, and decision-making tasks, as well as greater prepulse inhibition of the startle response, among val/val subjects administered tolcapone ([@R57]--[@R59]). However, one of these studies also examined a large number of cognitive measures, including other executive function and working memory measures, for which no pharmacogenetic effects were found. The two others included only homozygous subjects; thus, val/val subjects' tolcapone-induced cognitive improvement was in comparison to met/met subjects' decline. However, the only COMT inhibitor study that included a psychiatric population (treatment-seeking cigarette smokers) found better working memory performance and greater medial and dorsolateral PFC (DLPFC) activation during a working memory task among tolcapone-treated met-allele carriers, relative to val/val subjects ([@R60]).

Overall, extant data indicate weak evidence for val158met moderation of stimulant and COMT inhibitor effects on cognitive function. Strong evidence is limited to two studies of methylphenidate among Korean children with ADHD and three studies of tolcapone among healthy adults. Notably, the strongest and most consistent evidence of a pharmacogenetic effect is for tolcapone, which more specifically increases cortical DA, in contrast to stimulants, which increase DA throughout the brain.

Antipsychotics {#S8}
--------------

Antipsychotic effects on cortical DA concentrations are complex. First-generation, "typical" antipsychotics (e.g., haloperidol, sulpiride) act most strongly as D~2~ antagonists, and second- and third-generation, "atypical" antipsychotics (e.g., clozapine, olanzapine), in addition to D~2~ antagonism, also act as serotonergic antagonists or partial agonists. At therapeutic doses, these drugs have greater effects on post- than pre-synaptic D~2~ receptors ([@R37]), suggesting that, since post-synaptic D~2~ receptors are more prevalent in PFC, antipsychotics may bias PFC networks towards D~1~-dominated states ([@R61]). However, this effect may depend upon an individual's baseline DA tone, such that antipsychotics may also reduce tonically increased DA ([@R62]) (although this mechanism may be unique to drugs with DA partial agonist properties). [Table 2](#T2){ref-type="table"} lists studies that have tested moderation of the cognitive effects of antipsychotics by *COMT* val158met variation.

There is strong evidence for val158met pharmacogenetic moderation of antipsychotic effects on cognitive function. Seven studies have examined this phenomenon among psychiatric populations (primarily adults with psychotic disorders), and one has tested it among healthy controls. Since these disorders are relatively rare and subjects are often recruited from clinics, most studies have been small (range = 20--98 subjects) and have examined pharmacogenetic effects among patients already taking antipsychotics. All seven psychiatric studies have reported better drug effects among met/met subjects; three have also reported better effects among val/met, relative to val/val, subjects.

Three of the studies of psychiatric populations reported pharmacogenetic effects on specific cognitive functions. A small placebo-controlled crossover study of antipsychotics found pharmacogenetic moderation of drug effects on the *N-*back working memory task, but not other cognitive domains, such that antipsychotics, relative to placebo, improved performance only among met/met subjects ([@R63]). A study of olanzapine effects on changes in working memory over four weeks of treatment also found greater *N*-back improvement among met/met subjects relative to val-allele carriers ([@R64]). Because reduced DLPFC activation during the *N*-back was accompanied by performance improvements, greater reduction in DLPFC activation among met/met subjects was interpreted as evidence of increased cortical efficiency (e.g., less activation was required to produce better performance). Additionally, a study of patients who received both an antipsychotic and cognitive remediation therapy for 12 weeks found greater improvement among met-allele carriers relative to val/val subjects in processing speed, but not other cognitive functions ([@R65]). However, the pharmacogenetic interaction was only present for patients taking antipsychotics other than clozapine, and was driven by significantly worse performance among val/val subjects. In contrast, clozapine, which has greater D~1~ affinity than other antipsychotics, improved cognition irrespective of *COMT* genotype, suggesting that val158met pharmacogenetic effects might be specific to drugs with greater D~2~ effects.

The other four studies of psychiatric populations found pharmacogenetic effects on broader indices of cognitive function. In contrast to the Bosia et al. (2014) finding, another clozapine study reported greater improvement on a neurocognitive factor comprised of attention and verbal fluency measures among met-allele carriers relative to val/val subjects after six months of treatment ([@R66]). A study of antipsychotic effects on cognition found less "cognitive deterioration" (i.e., scores on "hold" tests that are stable in adulthood and insensitive to acquired brain damage, such as WAIS Vocabulary and Information, relative to tests that are sensitive to brain damage, such as WAIS Digit Symbol) among met/met subjects ([@R67]). Similarly, met-allele carriers treated with greater antipsychotic doses demonstrated higher WAIS verbal IQ, but not performance IQ, scores relative to val/val subjects administered the same doses ([@R68]). Finally, a small study of patients with bipolar spectrum disorders assessed change in cognition as a function of genotype and antipsychotic use during a two-year period. For subjects who used antipsychotics, there was less deterioration over time in a composite measure comprised of verbal learning and memory, selective attention, and working memory tasks among met/met subjects relative to val-allele carriers ([@R69]). Thus, taken together, it appears that val-allele homozygotes with psychotic disorders are most susceptible to interference in cognitive function from antipsychotic medications, perhaps because these individuals' D~1~/D~2~ balance is too low for antipsychotics to rescue.

A placebo-controlled study of the D~2~ antagonist sulpiride among healthy controls ([@R70]) reported contrasting findings to the antipsychotic studies among psychiatric subjects. Neurophysiological measures of error reactivity (e.g., EEG error-related negativity, error-related increases in delta/theta power, and post-error slowing) were obtained during a selective attention task. Under placebo, these measures were reduced in met/met subjects relative to val-allele carriers, suggesting more optimal cognitive function in the met/met group. Sulpiride reduced each measure in val-allele carriers but increased each in met/met subjects, suggesting that healthy controls, relative to individuals with schizophrenia spectrum disorders, might display a right-shifted inverted-U-shaped function under which D~2~ antagonism worsens met/met subjects' more optimal D~1~/D~2~ balance.

Overall, extant data indicate strong evidence for val158met moderation of antipsychotic effects on cognitive function. Studies have included a broad range of individuals with psychotic disorders, as well as a broad range of drugs. However, only one study has used a placebo-controlled crossover design, likely due to the difficulty of changing or discontinuing medications among individuals with severe and persistent mental illness. Additionally, although extant studies have reported pharmacogenetic effects on a variety of cognitive outcomes, few specific findings have been replicated; there is inconsistent evidence for a pharmacogenetic effect on any specific neurocognitive domain. Nonetheless, the *COMT* val158met SNP holds promise for predicting the effects of antipsychotics on cognitive function.

Discussion {#S9}
==========

This paper reviewed 25 studies of the moderating influence of the *COMT* val158met SNP on dopaminergic drug effects on PFC-dependent cognitive functions. These studies examined medications that modulate cortical D~1~ and D~2~ binding among both psychiatric populations and healthy controls. There was mixed evidence of pharmacogenetic effects for stimulants and COMT inhibitors, but stronger evidence for antipsychotics. COMT inhibitors improved cognitive function the most among val-allele homozygotes, while antipsychotics improved it the most among met-allele homozygotes (see [Figure 2](#F2){ref-type="fig"}). The implications of these findings in the context of the dual state theory of prefrontal DA and the inverted-U-shaped hypothesis are discussed below, as are directions for future work in this area.

Several factors may account for the weak evidence of pharmacogenetic effects for stimulants. First, stimulants' mechanism of action is not PFC-specific; stimulants non-selectively increase DA throughout the brain, most notably in the striatum ([@R71]). Thus, the beneficial effect of increasing cortical DA among individuals with low D~1~/high D~2~ occupancy (e.g., val-allele homozygotes) may be counteracted by increases in striatal DA, which, although it increases behavioral flexibility ([@R6]), is also associated with impulsivity and risky decision-making ([@R72]). Data that suggest that midbrain and striatal DA concentrations are positively associated with cortical blood flow in val-allele carriers but negatively associated in met/met subjects support this notion ([@R73]). Second, and relatedly, the primary outcome in most of the stimulant studies, ADHD symptoms, includes both PFC-mediated "cognitive" symptoms (e.g., inattention, distractibility) and motor and hyperactivity symptoms that are likely striatally mediated. Finally, in contrast to the antipsychotic studies, most of the stimulant studies reviewed had large sample sizes and employed placebo-controlled crossover designs, suggesting that weaker designs could lead to false positive findings. However, these design considerations were possible in part because of the greater prevalence of ADHD relative to schizophrenia spectrum disorders and the lower clinical risk in administering placebo medications to ADHD patients.

In contrast to the findings for stimulants, there was stronger evidence of pharmacogenetic moderation of the COMT inhibitor tolcapone. Studies were small and mostly limited to healthy controls, but consistently demonstrated greater drug effects among val/val subjects. As noted previously, tolcapone acutely increases DA most prominently in the PFC; thus, it is logical that val158met genotype would moderate its effects more powerfully than stimulants. Tolcapone has been used sparingly in clinical practice due to hepatoxicity concerns, but the findings reviewed here, as well as data suggesting that tolcapone may improve cognitive function independent of *COMT* genotype ([@R74]), have increased interest in its potential clinical utility ([@R38], [@R75]).

Evidence of a pharmacogenetic effect for antipsychotics was also strong. All seven studies of antipsychotics among psychiatric populations suggested that these drugs improved cognition (or prevented its deterioration) the most among met-allele homozygotes. Since antipsychotics increase cortical D~1~ binding and the *COMT* met allele may be associated with a more optimal D~1~/D~2~ balance, this pattern of results might seem counterintuitive. One possibility is that val158met variation may differentially impact D~1~/D~2~ balance among individuals with schizophrenia spectrum disorders as a function of the reduced cortical D~1~ function that may characterize these disorders ([@R76], [@R77]). Individuals with these disorders may be shifted leftward on the inverted-U-shaped function, leaving met-allele homozygotes' D~1~/D~2~ balance on the near left edge of the function and amenable to antipsychotic effects, but val-allele homozygotes' balance so dysregulated that antipsychotics cannot remediate it. Interestingly, the one antipsychotic study that included healthy controls, among whom cortical DA function is presumably normal, reported deleterious drug effects in met/met subjects, suggesting the pharmacogenetic interaction may indeed be population-specific. Alternatively, the relationship between cortical DA and some of the cognitive functions measured in these studies may not be inverted-U-shaped ([@R78]).

In the antipsychotic studies, there was considerable variability regarding the specific cognitive domains affected by the pharmacogenetic interaction. Data were most consistent for working memory; three of the four studies that examined this construct found pharmacogenetic effects on it. However, despite this strong evidence, there is limited evidence (not reviewed here) that val158met genotype moderates overall antipsychotic treatment response (e.g., decrease in schizophrenia symptoms or improvement in global functioning). Impairments in cognitive function represent only one aspect of schizophrenia spectrum disorders, and improving cognition may be of limited clinical benefit for individuals with these disorders.

Several factors limit interpretation of the data reviewed here. First, publication bias remains problematic for the pharmacogenetic literature, and effect sizes are often lower in replication studies ([@R79]). The val158met SNP is a sound candidate gene for moderation of dopaminergic drug effects---it has downstream functional effects and is related to the mechanism of action for these drugs---but studies of its potential pharmacogenetic effects must adhere to strong experimental design to reduce the likelihood of false-positive findings. Second, it is unclear whether race or ethnicity may influence val158met effects. The val allele is significantly more common among individuals of African and Asian descent, and the frequency of other polymorphisms that affect DA signaling also varies by race and ethnicity. These factors could result in differential epistatic interactions between val158met and these other polymorphisms. Thus, differences in pharmacogenetic effects by race and ethnicity should be examined when possible. Finally, none of the studies reviewed here addressed pharmacogenetic moderation of adverse drug effects. The val/val genotype may confer liability to the development of antipsychotic-induced tardive dyskinesia ([@R80]). Similarly, several of the studies reviewed here suggested that val-allele homozygotes with schizophrenia spectrum disorders administered antipsychotics experienced decreased cognitive function from these drugs, but this phenomenon has not been systematically reviewed.

Despite these limitations, there are many promising future directions for research in this area. First, val158met genotype will likely be most useful for predicting the cognitive effects of drugs that specifically target cortical DA. Most of the drugs used in the studies reviewed here affect DA, and other neurotransmitter systems, in areas beyond the PFC. Two notable exceptions that merit further pharmacogenetic research are COMT inhibitors, which have demonstrated some of the most promising pharmacogenetic results of any class of drugs, and second-generation antipsychotics with more prominent D~1~ effects (e.g., clozapine) or novel dopaminergic mechanisms of action (e.g., the D~2~ partial agonist aripiprazole). Second, future studies should expand the use of neuroimaging outcome measures, which are ideal intermediate phenotypes, and are arguably more likely to demonstrate genetic effects than behavioral measures ([@R28]). Only four studies reviewed here used fMRI, and all had among the smallest *N'*s of the identified studies. Large-scale imaging genetics studies that include drug challenges, though more difficult and expensive to conduct, would greatly improve confidence in extant pharmacogenetic findings. Related to this issue, the use of a common neurocognitive outcome measure (e.g., the NIH Toolbox multidimensional battery) in future research would facilitate comparison between studies. Third, in placebo-blinded studies, prospective genotyping should be used to ensure equal distribution of individuals with each *COMT* genotype to active and placebo medications; for studies of racial or ethnic populations in which one allele is significantly less frequent, this provision would be particularly useful for preventing small cell sizes, and thus imprecise estimates of drug effects. Finally, investigation of other *COMT* polymorphisms may be fruitful. A synonymous *COMT* SNP, rs4818, forms a haplotype with val158met that may predict COMT expression beyond the effects of either variant alone ([@R81]), and may moderate tolcapone effects on cognitive function ([@R82]). Other *COMT* SNPs have been reported to moderate risperidone response among patients with schizophrenia ([@R83], [@R84]), suggesting that val158met is only one of several functionally relevant *COMT* polymorphisms.

In conclusion, extant data suggest that variation at the *COMT* val158met SNP is a promising target for predicting the effects of dopaminergic drugs on PFC-dependent cognitive functions. Continued development of medications that specifically modulate cortical DA may ultimately allow this variant to guide a personalized medicine approach to cognition in a variety of neuropsychiatric disorders.

![Schematic of the hypothetical inverted-U-shaped relationship between cortical DA state and PFC-dependent cognitive function.](nihms784818f1){#F1}
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###### 

Studies of stimulants and COMT inhibitors and moderation by *COMT* val158met genotype

  First author, year                           Drug              Placebo-controlled   Population                              Total *N* (val/val, val/met, met/met)                Outcome measure(s)                                                                                                                                                                          Significant *COMT* x drug interaction                                                                                Group(s) w/best outcome:
  -------------------------------------------- ----------------- -------------------- --------------------------------------- ---------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------- --------------------------
  *Stimulants: healthy controls*                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
  Mattay, 2003                                 Amphetamine       Yes (crossover)      Healthy adults                          **25** (9, 10, 6)                                    **Executive function** (WCST), **working memory** (fMRI during *N*-back)                                                                                                                    Better WCST and *N*-back performance and reduced DLPFC activation during *N*- back in val/val                        **Val/val**
  Hamidovic, 2010                              Amphetamine       Yes (crossover)      Healthy adults (all Caucasian)          **161** (36, 72, 53)                                 **Selective attention** (DSST, Deviation from the Mode task)                                                                                                                                Better performance on all measures in val/val, val/met                                                               **Val/val,** val/met
  Hart, 2013                                   Amphetamine       Yes (crossover)      Healthy adults (all Caucasian)          **176** (50, 77, 49)                                 **Selective attention** (DSST)                                                                                                                                                              None                                                                                                                 None
  Wardle, 2013                                 Amphetamine       Yes (crossover)      Healthy adults                          **193** (56, 89, 48)                                 **Selective attention** (DSST), **executive function** (WCST), **working memory** (*N*-back)                                                                                                None                                                                                                                 None
  *Stimulants: psychiatric populations*                                                                                                                                                                                                                                                                                                                                                                                                                                                             
  Cheon, 2008                                  Methylphenidate   No                   Children w/ ADHD (all Korean)           **124** (68, 48, 8)                                  **ADHD sx** (≥50% decrease in teacher-rated ADHD-RS)                                                                                                                                        Greater likelihood of sx decrease in val/val                                                                         **Val/val**
  Kereszturi, 2008                             Methylphenidate   No                   Children w/ ADHD (all Caucasian)        **122** (39, 59, 24)                                 **ADHD sx** (≥25% decrease in clinician-rated ADHD-RS and CGI-S ≤ 2)                                                                                                                        Greater likelihood of sx decrease in val/val                                                                         **Val/val**
  Sengupta, 2008                               Methylphenidate   Yes (crossover)      Children w/ ADHD (all Caucasian)        **188** (46, 104, 38)                                **ADHD sx** (experimenter- rated RASS)                                                                                                                                                      None                                                                                                                 None
  McGough, 2009                                Methylphenidate   Yes (crossover)      Children w/ ADHD                        **82** (24, 39, 19)                                  **ADHD sx** (composite of teacher-rated ADHD-RS, SWAN, and PERMP)                                                                                                                           None                                                                                                                 None
  Froehlich, 2011                              Methylphenidate   Yes (crossover)      Children w/ ADHD                        **89** (30, 40, 19)                                  **ADHD sx** (composite of Vanderbilt ADHD Parent and Teacher Rating Scales)                                                                                                                 Trend (*p* = .09) for greater likelihood of hyperactive- impulsive sx decrease in in val/val                         **Val/val**
  Salatino- Oliveira, 2011                     Methylphenidate   No                   Male children w/ ADHD                   **112** (35, 77)[@](#TFN3){ref-type="table-fn"}      **ADHD sx** (parent-rated SNAP-IV)                                                                                                                                                          Greater reduction in oppositional sx after 1 month of treatment in val/met, met/met; no effect at 3 months           Val/met, *met/met*
  Contini, 2012                                Methylphenidate   No                   Adults w/ ADHD                          **164** (47, 117)                                    **ADHD sx** (≥30% decrease in SNAP-IV and CGI-S ≤ 2)                                                                                                                                        None                                                                                                                 None
  McCracken, 2014                              Methylphenidate   Yes (crossover)      Children w/ autism spectrum disorders   **57** (19, 38)[@](#TFN3){ref-type="table-fn"}       **Hyperactive-impulsive sx** (≥ 25% decrease in parent- /teacher-rated ABC and clinician-rated CGI-C ≤ 2)                                                                                   Greater likelihood of hyperactive-impulsive sx decrease in val/val                                                   **Val/val**
  Park, 2014                                   Methylphenidate   No                   Children w/ ADHD (all Korean)           **120** (70, 43, 7)                                  **ADHD sx** (≥50% decrease in parent-rated ADHD-RS), **selective attention** (≥10% decrease in CPT errors, RT,                                                                              Greater likelihood of hyperactive-impulsive sx decrease and CPT RT variability in val/val                            **Val/val**
  *COMT inhibitors: healthy controls*                                                                                                                                                                                                                                                                                                                                                                                                                                                               
  Apud, 2007                                   Tolcapone         Yes (crossover)      Healthy adults                          **47** (15, 21, 11)                                  and RT variability) **Executive function** (CANTAB ID/ED, Trails B, WCST**), selective attention** (CPT), **working memory** (*N*- back, LNS), **verbal fluency, verbal episodic memory**   Better CANTAB ID/ED performance in val/val; no effects on other tasks                                                **Val/val**
  Giakoumaki, 2008                             Tolcapone         Yes (crossover)      Healthy adult males                     **23** (12, 0, 11)[\*](#TFN2){ref-type="table-fn"}   **Working memory** (*N*-back, letter-number sequencing), **cognitive efficiency** (prepulse inhibition)                                                                                     Better performance on all measures in val/val                                                                        **Val/val**
  Farrell, 2012                                Tolcapone         Yes                  Healthy adult males                     **67** (33, 0 34)[\*](#TFN2){ref-type="table-fn"}    **Working memory** (*N*-back), **decision-making** (gambling                                                                                                                                Better performance on both measures in val/val                                                                       **Val/val**
  *COMT inhibitors: psychiatric populations*                                                                                                                                                                                                                                                                                                                                                                                                                                                        
  Ashare, 2013                                 Tolcapone         Yes (crossover)      Adults w/ nicotine dependence           **20** (9, 11)[@](#TFN3){ref-type="table-fn"}        task) **Working memory** (fMRI during *N-*back)                                                                                                                                             Better *N*-back performance and increased medial frontal, DLPFC activation during *N*- back in val/met and met/met   Val/met, *met/met*

**Abbreviations:** ABC = Aberrant Behavior Checklist; ADHD = Attention-deficit/hyperactivity disorder; ADHD-RS = ADHD Rating Scale IV; CANTAB ID/ED = Cambridge Neuropsychological Test Automated Battery Intradimensional/Extradimensional set-shifting test; CGI-C = Clinical Global Impression Global Improvement; CGI-S = Clinical Global Impression Severity; CPT = Continuous Performance Test; DLPFC = dorsolateral prefrontal cortex; DSST = Digit Symbol Substitution Test; LNS = letter-number sequencing; PERMP = Permanent Product Measure of Performance math test; POMS = Profile of Mood States; RASS = Restricted Academic Situation Scale; RT = response time; SNAP-IV = Swanson, Nolan and Pelham Scale-Version IV; SWAN = Strengths and Weaknesses of ADHD-Symptoms and Normal Behavior scale; sx = symptoms; WCST = Wisconsin Card-Sorting Task

Excluded val/met subjects

Second figure refers to the combined total of val/met and met/met subjects; study combined these groups for analysis.

###### 

Studies of antipsychotics and moderation by *COMT* val158met genotype

  First author, year    Drug                                                                             Placebo-controlled   Population                                       Total *N* (val/val, val/met, met/met)   Outcome measure(s)                                                                                                                      Significant *COMT* x drug interaction                                                                                                      Group(s) w/best outcome:
  --------------------- -------------------------------------------------------------------------------- -------------------- ------------------------------------------------ --------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------ --------------------------
  Bertolino, 2004       Olanzapine                                                                       No                   Adults w/ SZ or schizophreniform disorder        **30** (8, 17, 5)                       **Working memory** (fMRI during *N*-back)                                                                                               Greater improvement on *N*-back, less DLPFC activation during *N*- back in met/met                                                         *Met/met*
  Weickert, 2004        Antipsychotics[\*](#TFN5){ref-type="table-fn"}                                   Yes (crossover)      Adults w/ SZ or schizoaffective disorder         **20** (5, 11, 4)                       **Working memory** (*N*-back), **executive function** (WCST), **verbal fluency**, **overall cognitive function** (WAIS-R FSIQ, WMS-R)   Better *N*-back performance in met/met; no effects on other measures                                                                       *Met/met*
  Mata, 2006            Antipsychotics[\*](#TFN5){ref-type="table-fn"}                                   No                   Adults w/ non- affective psychotic disorders     **87** (23, 47, 17)                     **Overall cognitive function** (WAIS-III Vocabulary, Information, Digit-Symbol)                                                         Less cognitive deterioration (score on Digit-Symbol relative to Vocab and Info) in met/met                                                 *Met/met*
  Woodward, 2007        Clozapine                                                                        No                   Adults w/ SZ                                     **86** (29, 35, 21)                     **Attention and verbal fluency** (CIGT, COWAT, DSST), **memory** (ACTT, BSRT, WISC-R Mazes), **executive function** (WCST)              Greater improvement in attention and verbal fluency in met/met and val/met; no effects on memory, executive function                       *Met/met,* val/met
  Rebollo- Mesa, 2011   Antipsychotics[\*](#TFN5){ref-type="table-fn"}                                   No                   Adults w/ SZ (some concordant identical twins)   **68** (17, 36, 15)                     **Overall cognitive function** (WAIS-III VIQ, PIQ)                                                                                      Greater antipsychotic dose associated with greater VIQ in met/met and val/met; no effect on PIQ                                            *Met/met,* val/met
  Arts, 2013            Antipsychotics[\*](#TFN5){ref-type="table-fn"}                                   No                   Adults w/ bipolar spectrum disorders             **51** (7, 32, 12)                      **Verbal learning and memory** (VLT)**, selective attention** (Flanker CPT)**, working memory** (WAIS-III Digit Span Backward)          Less deterioration on composite of all three measures in met/met                                                                           *Met/met*
  Bosia, 2014           Antipsychotics[\*](#TFN5){ref-type="table-fn"} + cognitive remediation therapy   No                   Adults w/ SZ (all Caucasian)                     **98** (24, 50, 24)                     **Verbal memory, working memory, motor coordination, processing speed, verbal fluency, executive function** (BAC-S)                     Greater improvement on processing speed in met/met, val/met treated w/ antipsychotics other than clozapine; no effects on other subtests   *Met/met,* val/met
  *Healthy controls*                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
  Mueller, 2011         Sulpiride                                                                        Yes                  Healthy adult males                              **169** (33, 86, 50)                    **Selective attention** (EEG during Flanker CPT)                                                                                        Smaller error-related negativity, delta/theta power, and post-error slowing in val/val, val/met                                            **Val/val**, val/met

**Abbreviations:** ACTT = Auditory Consonant Trigram Test; BAC-S = Brief Assessment of Cognition in Schizophrenia; BSRT = Buschke Selective Reminding Task; CIGT = Category Instance Generation Test; CPT = Continuous Performance Test; COWAT = Controlled Oral Word Association Test; DLPFC = dorsolateral prefrontal cortex; DSST = Digit Symbol Substitution Test; EEG = electroencephalogram; FSIQ = Full Scale Intelligence Quotient; GAF = Global Assessment of Functioning; PIQ = Performance Intelligence Quotient; SZ = schizophrenia; VIQ = Verbal Intelligence Quotient; VLT = Verbal Learning Test; WAIS = Wechsler Adult Intelligence Scale (R = Revised, III = Third Edition); WCST = Wisconsin Card-Sorting Task; WISC-R = Wechsler Intelligence Scale for Children---Revised; WMS-R = Wechsler Memory Scale---Revised

Subjects prescribed various first- and second-generation antipsychotics were included.
